Artex, one of the largest global cell facility managers, announced today it will be transitioning all of its cell facility names to Artex Axcell over the next several months. The change aims to bring more efficiency and higher levels of service to clients seeking an alternative risk solution that demands less time, investment and resources.

"The creation of Artex Axcell is the result of a rationalization effort that will be phased across jurisdictions and will drive a consistent global approach," said Peter Mullen, Global CEO, Artex. "The new cell facility name is designed to highlight our best-in-class offering and build upon the strength and reputation of the Artex brand to entities across the US, Cayman, Bermuda and Guernsey."

Cell facilities can be used for a variety of purposes, including to gain greater (re)insurance and capital market access, provide flexibility in coverage, fill gaps in commercial policies, create new revenue streams, as an alternative to an owned captive and as a captive exit strategy.

Derived from the words "accelerate" and "cell," Artex Axcell represents a united, global approach for clients:

  • For organizations looking to lower total cost of risk and take more control than the traditional insurance market affords, Artex Axcell creatively brings a more efficient risk transfer vehicle with a lower investment of time, money and resources.
  • For capital market investors seeking a transformer structure, Artex Axcell is the market leader to advise, facilitate and execute these transactions quickly and effectively.

About Artex

Artex, Gallagher's wholly owned subsidiary for alternative risk and capital, including fund administration, is a trusted leader and provider of diverse alternative risk and capital solutions. Established in more than 35 domiciles internationally, our global team provides creative thinking and deep expertise for our clients in the (re)insurance and alternative capital marketplace. We're here to help you find a better way to reduce your total cost of risk and improve your return on capital.